Skip to main content

Advertisement

Table 1 Comparison responders - non responders

From: Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer

  Responders Non responders  
Variables (n = 269) (n = 29) P-value
Age (year) 66,4 ± 7,2 65,6 ± 7,9 0,67
Pre-treatment index of prostatic symptom score (IPSS) 4,1 ± 2,8 4,2 ± 2,8 0,75
Pre-treatment PSA (ng/ml) 6,7 ± 2,3 7,1 ± 2,4 0,32
Pre-treatment prostate volume (cm3) 34,2 ± 9,7 33,7 ± 9,6 0,89
Gleason score (% points)   0,52  
< VII 82 79  
VII 18 21  
Clinical tumour stage (% points)   0,43  
T1C 60 72  
T2 40 28  
Neoadjuvant hormonal therapy (% points) 27,5 38 0,28
Follow-up (year) 3,0 ± 1,5 2,6 ± 1,3 0,24
D90 (minimal dose received by 90% of the prostate gland) 159,8 ± 21,8 151,7 ± 21,7 0,08
U30* (minimal dose received by 30% of urethra) 215,5 ± 44,0 198,5 ± 40,0 0,06
V100* (percentage of the prostate volume receiving 100% of the prescribed dose) 87,7 ± 8,0 85,5 ± 7,6 0,09
V150* (percentage of the prostate volume receiving 150% of the prescribed dose.) 47,5 ± 14,6 43,0 ± 12,0 0,14
RV160* (surface of rectum receiving 160 Gy) 0,58 ± 0,76 0,42 ± 0,55 0,42
Number of implanted seeds 74,2 ± 11,7 72,1 ± 12,6 0,41
Number of implanted needles 21,2 ± 2,7 21,3 ± 3,0 0,87
  1. * measurements 30 days after implantation.